AgeX Therapeutics, Inc. (AGE)

NYSEAMERICAN: AGE · IEX Real-Time Price · USD
0.370
0.00 (0.00%)
Feb 23, 2024, 4:00 PM EST - Market closed
0.00%
Market Cap 14.04M
Revenue (ttm) 94,000
Net Income (ttm) -14.05M
Shares Out 37.95M
EPS (ttm) -0.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 21,698
Open 0.370
Previous Close 0.370
Day's Range 0.361 - 0.387
52-Week Range 0.310 - 1.000
Beta 1.22
Analysts n/a
Price Target n/a
Earnings Date Apr 1, 2024

About AGE

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 29, 2018
Employees 5
Stock Exchange NYSEAMERICAN
Ticker Symbol AGE
Full Company Profile

Financial Performance

In 2022, AGE's revenue was $34,000, a decrease of -76.39% compared to the previous year's $144,000. Losses were -$10.46 million, 20.6% more than in 2021.

Financial Statements

News

AgeX Therapeutics Reports Third Quarter 2023 Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and ope...

3 months ago - Business Wire

AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AgeX Therapeut...

6 months ago - Business Wire

Shareholder Alert: Ademi LLP investigates whether AgeX Therapeutics, Inc. has obtained a Fair Price in its transaction with Serina

MILWAUKEE , Aug. 30, 2023 /PRNewswire/ -- Ademi LLP is investigating AgeX (NYSE American: AGE) for possible breaches of fiduciary duty and other violations of law in its transaction with Serina. Click...

6 months ago - PRNewsWire

AGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of AgeX Therapeutics, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of AgeX Therapeutics, Inc. (NYSE: AGE) and Serina Therapeutics, Inc. is fair to AgeX share...

6 months ago - Business Wire

Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement

HUNTSVILLE, Ala. & ALAMEDA, Calif.--(BUSINESS WIRE)--Serina Therapeutics, Inc. (“Serina”), a privately-held, clinical-stage biotechnology company developing a pipeline of therapies for the treatment o...

6 months ago - Business Wire

AgeX Therapeutics Reports Second Quarter 2023 Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and ope...

6 months ago - Business Wire

AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred Stock

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported that on July 24, 2023...

7 months ago - Business Wire

AgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred Stock

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported that on July 21, 2023...

7 months ago - Business Wire

AgeX Therapeutics Announces Appeal of NYSE American Determination

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on May 17...

9 months ago - Business Wire

CORRECTING and REPLACING NYSE American to Commence Delisting Proceedings Against AgeX Therapeutics, Inc. (AGE)

NEW YORK--(BUSINESS WIRE)--Headline of release should read: NYSE American to Commence Delisting Proceedings Against AgeX Therapeutics, Inc. (AGE) (instead of NYSE American to Suspend Trading Immediate...

10 months ago - Business Wire

NYSE American to Suspend Trading Immediately in AgeX Therapeutics, Inc. (AGE) and Commence Delisting Proceedings

NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of ...

10 months ago - Business Wire

AgeX Therapeutics Reports First Quarter 2023 Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and ope...

10 months ago - Business Wire

AgeX Therapeutics Receives Stock Exchange Deficiency Letter

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics , Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on April...

10 months ago - Business Wire

AgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and ope...

11 months ago - Business Wire

AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on Nove...

1 year ago - Business Wire

AgeX Therapeutics Reports Third Quarter 2022 Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and o...

1 year ago - Business Wire

AgeX Therapeutics Reports Second Quarter 2022 Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and ope...

1 year ago - Business Wire

Dr. Joanne Hackett Appointed Chairperson of AgeX Board of Directors

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that Dr. Joann...

1 year ago - Business Wire

Early-Stage Investments for Turkish Metaverse Platform MetaAge Nears $1-Million Mark

ISTANBUL--(BUSINESS WIRE)--MetaAge, a metaverse platform based on the Solana Blockchain, has drawn almost $1 million in early-stage investments, project managers said this week. Currently, under devel...

1 year ago - Business Wire

AgeX Therapeutics Reports First Quarter 2022 Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and ope...

1 year ago - Business Wire

AgeX Therapeutics Reports Fourth Quarter and Annual 2021 Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and ope...

2 years ago - Business Wire

AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapies for Certain Brain Disorders

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today a r...

2 years ago - Business Wire

AgeX Therapeutics' Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today tha...

2 years ago - Business Wire

AgeX Therapeutics Reports Third Quarter 2021 Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and ope...

2 years ago - Business Wire

AgeX Therapeutics Reports Second Quarter 2021 Financial Results

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and ope...

2 years ago - Business Wire